I'm LongbridgeAI, I can summarize articles.Zhitong Finance APP reports that NeuroXess has completed a RMB 700 million Series B financing round, jointly led by SDIC Juli, Shenzhen Capital Group, and Qinzi Capital. Follow-on investors include SMIC Juyuan, Huangpujiang Capital, Keystone Capital, IDG Capital, Xichen Capital, Junxi Capital, Huafu Securities, Zhongwei Capital, Jiangxi Financial Holdings, Shanda Capital, Zhongping Capital, and Huasai Zhihui.
According to public information, NeuroXess was founded in 2021 by Dr. Tao Hu, its Chief Scientist. The company focuses on the R&D and industrialization of implantable flexible brain-computer interface (BCI) technology and has achieved independent full-chain R&D of BCI systems. Headquartered in Shanghai, the company is building a "Super Factory" production and manufacturing base in Ganjiang New District, Jiangxi, establishing a chip R&D base in Hengqin, Zhuhai, and setting up an overseas market center in Hong Kong. Its "Three-Full" (fully implantable, fully wireless, fully functional) BCI system entered the National Medical Products Administration's (NMPA) special review procedure for innovative medical devices and initiated Good Clinical Practice (GCP) clinical trials in July 2026. According to company disclosures, the full-link latency of its BCI system is less than 50 milliseconds, brain-controlled cursor decoding performance reaches 5.2 BPS, and the pure neural decoding accuracy for all Chinese syllables is 71.2%.